View ValuationAytu BioPharma 将来の成長Future 基準チェック /56Aytu BioPharmaは、112.2%と23.6%でそれぞれ年率112.2%で利益と収益が成長すると予測される一方、EPSはgrowで118.4%年率。主要情報112.2%収益成長率118.38%EPS成長率Pharmaceuticals 収益成長14.7%収益成長率23.6%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日10 Jun 2026今後の成長に関する最新情報Major Estimate Revision • May 20Consensus EPS estimates upgraded to US$1.40 lossThe consensus outlook for fiscal year 2026 has been updated. 2026 losses forecast to reduce from -US$1.68 to -US$1.40 per share. Revenue forecast steady at US$54.1m. Pharmaceuticals industry in the US expected to see average net income decline 13% next year. Consensus price target of US$9.33 unchanged from last update. Share price fell 4.4% to US$2.15 over the past week.Major Estimate Revision • Apr 19Consensus EPS estimates upgraded to US$1.68 loss, revenue downgradedThe consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast fell from US$57.1m to US$54.0m. 2026 losses expected to reduce from -US$1.90 to -US$1.68 per share. Pharmaceuticals industry in the US expected to see average net income decline 14% next year. Consensus price target down from US$9.67 to US$9.33. Share price was steady at US$2.60 over the past week.Major Estimate Revision • Feb 10Consensus EPS estimates fall by 85%, revenue upgradedThe consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast increased from US$55.3m to US$59.1m. Forecast EPS reduced from -US$1.03 to -US$1.90 per share. Pharmaceuticals industry in the US expected to see average net income growth of 1.6% next year. Consensus price target of US$9.33 unchanged from last update. Share price fell 13% to US$2.29 over the past week.Major Estimate Revision • Jan 22Consensus EPS estimates upgraded to US$1.03 lossThe consensus outlook for fiscal year 2026 has been updated. 2026 losses forecast to reduce from -US$1.14 to -US$1.03 per share. Revenue forecast unchanged from US$55.3m at last update. Pharmaceuticals industry in the US expected to see average net income growth of 1.1% next year. Consensus price target of US$9.33 unchanged from last update. Share price was steady at US$2.71 over the past week.分析記事 • Nov 17Aytu BioPharma, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This YearAytu BioPharma, Inc. ( NASDAQ:AYTU ) came out with its quarterly results last week, and we wanted to see how the...Major Estimate Revision • Sep 30Consensus revenue estimates fall by 22%The consensus outlook for revenues in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from US$70.5m to US$55.2m. Forecast losses increased from -US$0.85 to -US$1.55 per share. Pharmaceuticals industry in the US expected to see average net income decline 3.2% next year. Consensus price target down from US$9.67 to US$9.17. Share price fell 25% to US$1.88 over the past week.すべての更新を表示Recent updatesMajor Estimate Revision • May 20Consensus EPS estimates upgraded to US$1.40 lossThe consensus outlook for fiscal year 2026 has been updated. 2026 losses forecast to reduce from -US$1.68 to -US$1.40 per share. Revenue forecast steady at US$54.1m. Pharmaceuticals industry in the US expected to see average net income decline 13% next year. Consensus price target of US$9.33 unchanged from last update. Share price fell 4.4% to US$2.15 over the past week.Reported Earnings • May 15Third quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2026 results: US$0.53 loss per share (down from US$0.64 profit in 3Q 2025). Revenue: US$12.4m (down 33% from 3Q 2025). Net loss: US$5.62m (down 243% from profit in 3Q 2025). Revenue exceeded analyst estimates by 3.0%. Earnings per share (EPS) missed analyst estimates by 3.9%. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 8.7% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.お知らせ • May 07Aytu BioPharma, Inc. to Report Q3, 2026 Results on May 13, 2026Aytu BioPharma, Inc. announced that they will report Q3, 2026 results at 4:00 PM, US Eastern Standard Time on May 13, 2026Major Estimate Revision • Apr 19Consensus EPS estimates upgraded to US$1.68 loss, revenue downgradedThe consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast fell from US$57.1m to US$54.0m. 2026 losses expected to reduce from -US$1.90 to -US$1.68 per share. Pharmaceuticals industry in the US expected to see average net income decline 14% next year. Consensus price target down from US$9.67 to US$9.33. Share price was steady at US$2.60 over the past week.Major Estimate Revision • Feb 10Consensus EPS estimates fall by 85%, revenue upgradedThe consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast increased from US$55.3m to US$59.1m. Forecast EPS reduced from -US$1.03 to -US$1.90 per share. Pharmaceuticals industry in the US expected to see average net income growth of 1.6% next year. Consensus price target of US$9.33 unchanged from last update. Share price fell 13% to US$2.29 over the past week.New Risk • Feb 08New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: US$25m Forecast net loss in 2 years: US$432k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (75% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$432k net loss in 2 years). Market cap is less than US$100m (US$25.7m market cap).Reported Earnings • Feb 04Second quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behindSecond quarter 2026 results: US$1.06 loss per share (down from US$0.11 profit in 2Q 2025). Revenue: US$15.2m (down 6.5% from 2Q 2025). Net loss: US$10.6m (down US$11.2m from profit in 2Q 2025). Revenue exceeded analyst estimates by 25%. Earnings per share (EPS) missed analyst estimates by 75%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 8.8% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 104% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.お知らせ • Jan 28Aytu BioPharma, Inc. to Report Q2, 2026 Results on Feb 03, 2026Aytu BioPharma, Inc. announced that they will report Q2, 2026 results After-Market on Feb 03, 2026Major Estimate Revision • Jan 22Consensus EPS estimates upgraded to US$1.03 lossThe consensus outlook for fiscal year 2026 has been updated. 2026 losses forecast to reduce from -US$1.14 to -US$1.03 per share. Revenue forecast unchanged from US$55.3m at last update. Pharmaceuticals industry in the US expected to see average net income growth of 1.1% next year. Consensus price target of US$9.33 unchanged from last update. Share price was steady at US$2.71 over the past week.分析記事 • Dec 20Aytu BioPharma, Inc. (NASDAQ:AYTU) Stock Catapults 28% Though Its Price And Business Still Lag The IndustryAytu BioPharma, Inc. ( NASDAQ:AYTU ) shares have had a really impressive month, gaining 28% after a shaky period...分析記事 • Nov 17Aytu BioPharma, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This YearAytu BioPharma, Inc. ( NASDAQ:AYTU ) came out with its quarterly results last week, and we wanted to see how the...New Risk • Nov 16New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: US$13m Forecast net loss in 2 years: US$1.6m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (66% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$1.6m net loss in 2 years). Market cap is less than US$100m (US$21.3m market cap).お知らせ • Nov 06Aytu BioPharma, Inc. to Report Q1, 2026 Results on Nov 13, 2025Aytu BioPharma, Inc. announced that they will report Q1, 2026 results After-Market on Nov 13, 2025分析記事 • Oct 30There's No Escaping Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Muted Revenues Despite A 27% Share Price RiseThose holding Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shares would be relieved that the share price has rebounded 27% in...お知らせ • Oct 27Aytu BioPharma, Inc., Annual General Meeting, Dec 10, 2025Aytu BioPharma, Inc., Annual General Meeting, Dec 10, 2025. Location: 7900 east union avenue, suite 920, colorado 80237, denver United StatesMajor Estimate Revision • Sep 30Consensus revenue estimates fall by 22%The consensus outlook for revenues in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from US$70.5m to US$55.2m. Forecast losses increased from -US$0.85 to -US$1.55 per share. Pharmaceuticals industry in the US expected to see average net income decline 3.2% next year. Consensus price target down from US$9.67 to US$9.17. Share price fell 25% to US$1.88 over the past week.Reported Earnings • Sep 24Full year 2025 earnings: EPS and revenues miss analyst expectationsFull year 2025 results: US$2.26 loss per share (improved from US$2.86 loss in FY 2024). Revenue: US$66.4m (down 18% from FY 2024). Net loss: US$14.2m (loss narrowed 11% from FY 2024). Revenue missed analyst estimates by 4.0%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 8.6% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 125% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.お知らせ • Sep 17Aytu BioPharma, Inc. to Report Q4, 2025 Results on Sep 23, 2025Aytu BioPharma, Inc. announced that they will report Q4, 2025 results After-Market on Sep 23, 2025分析記事 • Jul 29Improved Revenues Required Before Aytu BioPharma, Inc. (NASDAQ:AYTU) Stock's 25% Jump Looks JustifiedAytu BioPharma, Inc. ( NASDAQ:AYTU ) shares have continued their recent momentum with a 25% gain in the last month...Breakeven Date Change • Jun 30Forecast breakeven date pushed back to 2026The analyst covering Aytu BioPharma previously expected the company to break even in 2025. New forecast suggests the company will make a profit of US$1.66m in 2026. Average annual earnings growth of 77% is required to achieve expected profit on schedule.New Risk • Jun 13New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 61% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (30% average weekly change). Shareholders have been substantially diluted in the past year (61% increase in shares outstanding). Minor Risk Market cap is less than US$100m (US$17.5m market cap).お知らせ • Jun 03Aytu BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $12 million.Aytu BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $12 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 6,741,573 Price\Range: $1.78 Discount Per Security: $0.1246 Security Name: Prefunded Warrants Security Type: Equity Warrant Securities Offered: 6,741,573Reported Earnings • May 15Third quarter 2025 earnings: EPS and revenues exceed analyst expectationsThird quarter 2025 results: EPS: US$0.64 (up from US$0.52 loss in 3Q 2024). Revenue: US$18.5m (up 2.6% from 3Q 2024). Net income: US$3.94m (up US$6.83m from 3Q 2024). Profit margin: 21% (up from net loss in 3Q 2024). Revenue exceeded analyst estimates by 34%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to stay flat during the next 3 years compared to a 8.3% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 122% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.分析記事 • May 14We Think Some Shareholders May Hesitate To Increase Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO CompensationKey Insights Aytu BioPharma will host its Annual General Meeting on 21st of May Total pay for CEO Josh Disbrow includes...お知らせ • May 08Aytu BioPharma, Inc. to Report Q3, 2025 Results on May 14, 2025Aytu BioPharma, Inc. announced that they will report Q3, 2025 results After-Market on May 14, 2025分析記事 • May 04Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Price Is Right But Growth Is Lacking After Shares Rocket 27%Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shareholders are no doubt pleased to see that the share price has bounced 27% in...お知らせ • Mar 31Aytu BioPharma, Inc., Annual General Meeting, May 21, 2025Aytu BioPharma, Inc., Annual General Meeting, May 21, 2025. Location: at the office of aytu biopharma, inc., 7900 east union avenue, suite 920, colorado 80237, denver United StatesReported Earnings • Feb 13Second quarter 2025 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2025 results: EPS: US$0.11. Revenue: US$16.2m (down 14% from 2Q 2024). Net income: US$665.0k (up 7.4% from 2Q 2024). Profit margin: 4.1% (up from 3.3% in 2Q 2024). Revenue exceeded analyst estimates by 4.3%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to stay flat during the next 3 years compared to a 8.6% growth forecast for the Pharmaceuticals industry in the US.分析記事 • Jan 18Aytu BioPharma, Inc. (NASDAQ:AYTU) Shares Fly 28% But Investors Aren't Buying For GrowthAytu BioPharma, Inc. ( NASDAQ:AYTU ) shareholders are no doubt pleased to see that the share price has bounced 28% in...Reported Earnings • Nov 15First quarter 2025 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2025 results: EPS: US$0.18 (up from US$1.48 loss in 1Q 2024). Revenue: US$16.6m (down 25% from 1Q 2024). Net income: US$1.09m (up US$9.21m from 1Q 2024). Profit margin: 6.6% (up from net loss in 1Q 2024). Revenue exceeded analyst estimates by 20%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is expected to decline by 7.4% p.a. on average during the next 2 years, while revenues in the Pharmaceuticals industry in the US are expected to grow by 10%.分析記事 • Nov 15Investors Don't See Light At End Of Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Tunnel And Push Stock Down 32%To the annoyance of some shareholders, Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shares are down a considerable 32% in the...お知らせ • Nov 14Aytu Biopharma, Inc. Announces Chief Financial Officer ChangesAytu BioPharma, Inc. announced the promotion of Ryan Selhorn, current Executive Vice President of Finance and Business Optimization, to the role of Chief Financial Officer, replacing Mark Oki, who will depart the company. Prior to Ryan's appointment as Chief Financial Officer, he served as Aytu's Executive Vice President, Finance and Business Optimization since November 2022. Prior to this, Ryan was Aytu's Senior Vice President, Finance and Operations, Consumer Healthcare Division from February 2022 to November 2022 and as Vice President, Finance, Consumer Healthcare Division from February 2020 to February 2022. Ryan served as Vice President and Chief Financial Officer from April 2018 at Innovus Pharmaceuticals, Inc. until Aytu's acquisition of Innovus in February 2020. From August 2013 to April 2018, Ryan served as Chief Financial Officer and Chief Accounting Officer of Signature Analytics, where he also served as Chief Financial Officer of Medicinova, Inc. Ryan worked at Grant Thornton LLP, from October 2003 to July 2013, most recently in the role of Senior Manager, Transaction Advisory Services. Ryan received his B.S./B.A., Accounting and Finance from Georgetown University and is a Certified Public Accountant (inactive).お知らせ • Nov 07Aytu BioPharma, Inc. to Report Q1, 2025 Results on Nov 13, 2024Aytu BioPharma, Inc. announced that they will report Q1, 2025 results After-Market on Nov 13, 2024分析記事 • Nov 01Is Aytu BioPharma (NASDAQ:AYTU) Using Debt Sensibly?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Reported Earnings • Sep 27Full year 2024 earnings: EPS misses analyst expectationsFull year 2024 results: US$2.86 loss per share (improved from US$5.11 loss in FY 2023). Revenue: US$81.0m (down 25% from FY 2023). Net loss: US$15.8m (loss narrowed 7.1% from FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 15%. Revenue is expected to decline by 8.2% p.a. on average during the next 2 years, while revenues in the Pharmaceuticals industry in the US are expected to grow by 10%.お知らせ • Sep 20Aytu BioPharma, Inc. to Report Q4, 2024 Results on Sep 26, 2024Aytu BioPharma, Inc. announced that they will report Q4, 2024 results After-Market on Sep 26, 2024お知らせ • Aug 07An unknown buyer acquired Innovus Pharmaceuticals, Inc. from Aytu BioPharma, Inc. (NasdaqCM:AYTU).An unknown buyer acquired Innovus Pharmaceuticals, Inc. from Aytu BioPharma, Inc. (NasdaqCM:AYTU) on August 6, 2024. Aytu to receive revenue-based royalty payments on future sales of former Consumer Health business products. An unknown buyer completed the acquisition of Innovus Pharmaceuticals, Inc. from Aytu BioPharma, Inc. (NasdaqCM:AYTU) on August 6, 2024.New Risk • Jun 23New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 8.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (8.1% increase in shares outstanding). Market cap is less than US$100m (US$17.4m market cap).分析記事 • Jun 20It's Probably Less Likely That Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Will See A Huge Pay Rise This YearKey Insights Aytu BioPharma will host its Annual General Meeting on 26th of June Salary of US$590.0k is part of CEO...分析記事 • Jun 14Here's Why Aytu BioPharma (NASDAQ:AYTU) Has A Meaningful Debt BurdenSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Major Estimate Revision • May 22Consensus EPS estimates fall by 12%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from US$83.6m to US$81.3m. Losses expected to increase from US$2.23 per share to US$2.49. Pharmaceuticals industry in the US expected to see average net income growth of 3.3% next year. Consensus price target of US$8.00 unchanged from last update. Share price rose 2.3% to US$3.13 over the past week.Reported Earnings • May 17Third quarter 2024 earnings: EPS and revenues exceed analyst expectationsThird quarter 2024 results: US$0.52 loss per share (improved from US$1.93 loss in 3Q 2023). Revenue: US$18.0m (down 21% from 3Q 2023). Net loss: US$2.89m (loss narrowed 60% from 3Q 2023). Revenue exceeded analyst estimates by 3.7%. Earnings per share (EPS) also surpassed analyst estimates by 19%. Revenue is expected to decline by 9.9% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in the US are expected to grow by 9.4%.お知らせ • May 14Aytu BioPharma, Inc., Annual General Meeting, Jun 26, 2024Aytu BioPharma, Inc., Annual General Meeting, Jun 26, 2024. Location: dorsey & whitney llp, 1400 wewatta street, suite 400, colorado 80202, , denver United Statesお知らせ • May 10Aytu BioPharma, Inc. to Report Q3, 2024 Results on May 15, 2024Aytu BioPharma, Inc. announced that they will report Q3, 2024 results After-Market on May 15, 2024分析記事 • Feb 17US$8.00 - That's What Analysts Think Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Worth After These ResultsAytu BioPharma, Inc. ( NASDAQ:AYTU ) just released its latest quarterly results and things are looking bullish. Results...分析記事 • Feb 16Aytu BioPharma, Inc. (NASDAQ:AYTU) Surges 25% Yet Its Low P/S Is No Reason For ExcitementDespite an already strong run, Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shares have been powering on, with a gain of 25% in...Reported Earnings • Feb 16Second quarter 2024 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2024 results: US$0.04 loss per share (improved from US$2.15 loss in 2Q 2023). Revenue: US$22.9m (down 13% from 2Q 2023). Net loss: US$220.0k (loss narrowed 97% from 2Q 2023). Revenue exceeded analyst estimates by 5.5%. Earnings per share (EPS) also surpassed analyst estimates by 84%. Revenue is expected to decline by 12% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in the US are expected to grow by 9.0%.お知らせ • Feb 08Aytu BioPharma, Inc. to Report Q2, 2024 Results on Feb 14, 2024Aytu BioPharma, Inc. announced that they will report Q2, 2024 results After-Market on Feb 14, 2024分析記事 • Jan 23Does Aytu BioPharma (NASDAQ:AYTU) Have A Healthy Balance Sheet?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Price Target Changed • Dec 29Price target decreased by 95% to US$5.00Down from US$110, the current price target is provided by 1 analyst. New target price is 67% above last closing price of US$2.99. Stock is down 19% over the past year. The company is forecast to post a net loss per share of US$2.17 next year compared to a net loss per share of US$5.11 last year.お知らせ • Nov 08Aytu BioPharma, Inc. to Report Q1, 2024 Results on Nov 14, 2023Aytu BioPharma, Inc. announced that they will report Q1, 2024 results After-Market on Nov 14, 2023お知らせ • Oct 27Aytu BioPharma, Inc. Announces Approval of the Cotempla XR-ODT Manufacturing Site Transfer Prior Approval SupplementAytu BioPharma, Inc. announced receipt of U.S. Food & Drug Administration (FDA) approval of the Cotempla XR-ODT® ("Cotempla") Prior Approval Supplement (PAS). This approval enables the transfer of manufacturing of Cotempla to the Company's third-party manufacturer and follows a similar achievement for Adzenys XR- ODT® ("Adzenys") which received PAS approval in April 2023. Aytu is committed to a consistent and orderly transition of production to the new manufacturing facility in the coming months to ensure adequate inventory is available to meet the recent surge in prescription growth experienced for both Adzenys and Cotempla.お知らせ • Oct 01Aytu BioPharma, Inc. announced delayed annual 10-K filingOn 09/29/2023, Aytu BioPharma, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.分析記事 • Sep 29Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Share Price Boosted 59% But Its Business Prospects Need A Lift TooAytu BioPharma, Inc. ( NASDAQ:AYTU ) shareholders have had their patience rewarded with a 59% share price jump in the...Reported Earnings • Sep 28Full year 2023 earnings: EPS and revenues exceed analyst expectationsFull year 2023 results: US$5.11 loss per share (improved from US$74.95 loss in FY 2022). Revenue: US$107.4m (up 11% from FY 2022). Net loss: US$17.1m (loss narrowed 85% from FY 2022). Revenue exceeded analyst estimates by 2.9%. Earnings per share (EPS) also surpassed analyst estimates by 17%. Revenue is expected to decline by 6.1% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in the US are expected to grow by 7.3%.お知らせ • Sep 22Aytu BioPharma, Inc. to Report Q4, 2023 Results on Sep 27, 2023Aytu BioPharma, Inc. announced that they will report Q4, 2023 results After-Market on Sep 27, 2023お知らせ • Jul 11Aytu BioPharma, Inc. Announces Submission of Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval SupplementAytu BioPharma, Inc. submitted the Cotempla XR-ODT®? ("Cotempla") Prior Approval Supplement (PAS) to the U.S. Food & Drug Administration (FDA). If approved, the PAS would enable Aytu to transfer the production of Cotempla to the Company's third-party manufacturer. The Company expects a six-month review of the PAS submission, which would enable FDA approval by late calendar 2023 or early calendar 2024. The Company previously announced the FDA approval of the Adzenys XR-ODT (Adzenys) site transfer PAS and has begun shifting Adzenys production to the Company's contract manufacturer.お知らせ • Jun 14Aytu BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $3.999955 million.Aytu BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $3.999955 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,743,695 Price\Range: $1.84 Discount Per Security: $0.1288 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 430,217 Price\Range: $1.8399 Discount Per Security: $0.1288お知らせ • Jun 10+ 1 more updateAytu BioPharma, Inc. Appoints Abhinav "Abi" Jain as Board of DirectorsAytu BioPharma, Inc. announced the appointment of Abhinav "Abi" Jain of Nantahala Capital Management, LLC as the Company's Board of Directors as Board of Directors. Abi Jain is an Analyst at Nantahala, focused on investments in various sectors, including specialty and generic pharmaceuticals. Prior to joining Nantahala in 2019, Mr. Jain was an Associate at Angelo, Gordon &Co., an alternative asset manager based in New York from 2015-2017. At Angelo, Gordon &Co., Mr. Jain focused on private equity and structured credit investments. He graduated from Massachusetts Institute of Technology in 2012 with an S.B. in Chemical-Biological Engineering and from The Wharton School of the University of Pennsylvania in 2019 with an M.B.A. with honors in Finance and Entrepreneurial Management.Breakeven Date Change • Jun 10Forecast to breakeven in 2025The 2 analysts covering Aytu BioPharma expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 68% per year to 2024. The company is expected to make a profit of US$8.20m in 2025. Average annual earnings growth of 66% is required to achieve expected profit on schedule.Major Estimate Revision • May 18Consensus EPS estimates fall by 31%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from US$108.1m to US$102.8m. Losses expected to increase from US$4.78 per share to US$6.24. Pharmaceuticals industry in the US expected to see average net income decline 7.8% next year. Consensus price target of US$70.00 unchanged from last update. Share price fell 14% to US$1.81 over the past week.Breakeven Date Change • May 15Forecast to breakeven in 2024The 2 analysts covering Aytu BioPharma expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 88% to 2023. The company is expected to make a profit of US$900.0k in 2024. Average annual earnings growth of 149% is required to achieve expected profit on schedule.お知らせ • Feb 16Aytu BioPharma, Inc. announced delayed 10-Q filingOn 02/15/2023, Aytu BioPharma, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jan 26Aytu Biopharma Regains Nasdaq Minimum Bid Price ComplianceAytu BioPharma, Inc. (the Company or "Aytu") announced that it received a written notification from the Listing Qualifications Department of The Nasdaq Stock Market, LLC ("Nasdaq") notifying the Company that it has regained compliance with the Nasdaq's minimum bid price requirement. On January 23, 2023, Nasdaq confirmed in that for the ten consecutive business days, from January 6, 2023 to January 20, 2023, the closing bid price of the Company's common stock has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2), and the matter is closed.お知らせ • Jan 11Aytu Biopharma, Inc. Continues Availability of Adzenys XR-ODT(R) as the Only FDA-Approved Orally Disintegrating Tablet (ODT) Medication That Is Bioequivalent to Adderall XR(R) for Adhd PatientsAytu RxConnect Providing Access Relief to Patients Amid Ongoing Generic Adderall® Supply Disruption. Millions of ADHD patients in the United States rely on FDA approved treatments to control their ADHD symptoms and many of them are currently struggling to fill their prescription due to a prolonged supply disruption for generic Adderall XR (mixed salts of a single-entity amphetamine product) extended-release capsules, CII. Many of these patients may not be aware that there's an FDA-approved, bioequivalent treatment option which is widely available. As the only FDA-approved Orally Disintegrating Tablet bioequivalent to Adderall XR, Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets, CII is bridging the access gap resulting from the current supply disruption, as well as the shortage of Adderall IR. Aytu BioPharma, Inc. Adzenys XR-ODT is available as a potential treatment option to Adderall XR in six equivalent strengths. As healthcare insurance resets in January, many ADHD patients with high deductibles may face another challenge in accessing their medication. However, patients facing insurance challenges can gain access to Adzenys XR-ODT via Aytu's proprietary RxConnect program and the company's network of more than 1,000 retail pharmacies. The program is designed specifically to help patients navigate complex treatment journeys. It enables affordable, predictable patient access to Aytu Rx products and reduces out-of-pocket costs by 50 percent. In most cases, commercially insured patients will pay no more than $35 for their monthly prescription of Adzenys XR-ODT.Major Estimate Revision • Nov 21Consensus forecasts updatedThe consensus outlook for 2023 has been updated. 2023 losses forecast to reduce from -US$0.49 to -US$0.22 per share. Revenue forecast steady at US$109.0m. Pharmaceuticals industry in the US expected to see average net income growth of 4.5% next year. Consensus price target of US$5.50 unchanged from last update. Share price rose 11% to US$0.23 over the past week.Breakeven Date Change • Nov 16Forecast to breakeven in 2025The analyst covering Aytu BioPharma expects the company to break even for the first time. New forecast suggests losses will reduce by 74% per year to 2024. The company is expected to make a profit of US$2.80m in 2025. Average annual earnings growth of 76% is required to achieve expected profit on schedule.Reported Earnings • Nov 16First quarter 2023 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2023 results: US$0.057 loss per share (improved from US$1.09 loss in 1Q 2022). Revenue: US$27.7m (up 26% from 1Q 2022). Net loss: US$2.88m (loss narrowed 90% from 1Q 2022). Revenue exceeded analyst estimates by 14%. Earnings per share (EPS) also surpassed analyst estimates by 67%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Pharmaceuticals industry in the US.Seeking Alpha • Oct 13Aytu stock falls amid suspending clinical programs to save costsAytu BioPharma (NASDAQ:AYTU) stock dipped ~5% on Oct. 13 after the company said it was indefinitely suspending certain clinical development programs, thus expecting to save over $20M. The suspension includes AR101/enzastaurin for treat Vascular Ehlers-Danlos Syndrome (VEDS), Healight, and NT0502. Aytu is expecting to generate positive quarterly adjusted EBITDA in H1 calendar year 2023. "This strategic realignment enables us to dedicate our resources to growing our prescription and consumer health segments. Coupled with the suspension of clinical development activities and continued execution against our previously planned $15 million cost cutting program, this shift enables the Company to achieve near-term positive Adjusted EBITDA," said Aytu CEO Josh Disbrow in an Oct. 13 press release. The company expects to provide a detailed financial outlook of its strategy at its quarterly investors call scheduled for mid-November.Major Estimate Revision • Oct 04Consensus estimates of losses per share improve by 28%The consensus outlook for earnings per share (EPS) in 2023 has improved. 2023 revenue forecast increased from US$107.1m to US$110.1m. EPS estimate increased from -US$0.68 per share to -US$0.49 per share. Pharmaceuticals industry in the US expected to see average net income decline 2.3% next year. Consensus price target of US$5.50 unchanged from last update. Share price rose 2.6% to US$0.19 over the past week.Reported Earnings • Sep 28Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2022 results: US$3.75 loss per share (further deteriorated from US$3.48 loss in FY 2021). Revenue: US$96.7m (up 47% from FY 2021). Net loss: US$110.2m (loss widened 89% from FY 2021). Revenue exceeded analyst estimates by 2.1%. Earnings per share (EPS) missed analyst estimates by 4.9%. Revenue is forecast to grow 8.7% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Pharmaceuticals industry in the US.Seeking Alpha • Sep 27Aytu BioScience GAAP EPS of -$0.49 misses by $0.12, revenue of $27.45M beats by $1.95MAytu BioScience press release (NASDAQ:AYTU): FQ4 GAAP EPS of -$0.49 misses by $0.12. Revenue of $27.45M (+16.9% Y/Y) beats by $1.95M. Cash and cash equivalents at the end of the fiscal year ended June 30, 2022 were $19.4 million. Subsequent to the end of the year, the Company raised $10.0 million in gross proceeds in a registered public offering. Prescription segment Adjusted EBITDA was a positive $1.1 million, while Consumer Health was $(2.1) million resulting in a combined Adjusted EBITDA of $(1.0) million for the Company's commercial business. This compares to Adjusted EBITDA of $(5.5) million for the Prescription segment and $(2.7) million for the Consumer Health segment in Q4 2021, resulting in a combined Adjusted EBITDA of $(8.2) million for the Company's commercial business. Shares +5.26%.Seeking Alpha • Sep 14Aytu Biopharma adds fourth patent license for AR101 to treat rare genetic disorderAytu BioPharma (NASDAQ:AYTU) announced on Wednesday the addition of a fourth patent for AR101/Enzastaurin to treat Vascular Ehlers-Danlos Syndrome, rare genetic disorder treatment. The patent has an expiry date of September 2041. The company expects to advance the PREVEnt Trial in VEDS for AR101 and dose the first patient by early 2023. "Adding this fourth patent to the portfolio deepens and broadens the intellectual property surrounding AR101/Enzastaurin for the treatment of inherited vascular disorders, including VEDS, for which we are advancing AR101 as an initial indication," the company said. Vascular Ehlers-Danlos syndrome (vEDS) is the most severe type of a hereditary disorder of the connective tissue. (AYTU) had risen 3.3% before the bell.Seeking Alpha • Aug 16Aytu gets US patent for AR101/Enzastaurin for circulatory system disordersAytu BioPharma (NASDAQ:AYTU) said the U.S. Patent and Trademark Office issued a patent, a first for AR101/Enzastaurin. The U.S. patent No. 11,273,148 titled 'Targeted Epigenetic Therapy for Inherited Aortic Aneurism Condition,' covers methods for the targeted epigenetic therapy of inherited aortic aneurysm and other diseases with altered regulation of TGFβ genes, including Ehlers-Danlos Syndrome, the company said in an Aug. 16 press release. Aytu added that it was the first issued patent supporting the portfolio and expires in August of 2038, if not extended. "This issued patent underpins the broad potential clinical application across numerous inherited vascular disorders, including vascular Ehlers-Danlos Syndrome ("VEDS"), for which we are advancing AR101 as an initial indication. We expect to progress the PREVEnt Trial in VEDS for AR101 and dose the first patient by early 2023," said Aytu CEO Josh Disbrow. AYTU +0.59% to $0.29 premarket Aug. 16Seeking Alpha • Aug 09Aytu BioPharma plunges on pricing $10M stock and warrants offeringAytu BioPharma (NASDAQ:AYTU) priced its underwritten public offering of 21.5M shares to certain investors, pre-funded warrants to purchase 1.75M shares and accompanying warrants to purchase 23.2M shares,. The combined public offering price for each share of common stock and accompanying common warrant is $0.43 and combined offering price for each pre-funded warrant and accompanying common warrant is $0.429. Gross proceeds are expected to be ~$10M. Offer is expected to close on Aug.11. Net proceeds to be used for advancing the development of its pipeline assets, including for advancing the PREVEnt Trial evaluating AR101 for the treatment of vascular Ehlers-Danlos Syndrome, for growth of the company's commercial business, and for working capital and general corporate purposes.Major Estimate Revision • May 23Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 expected loss increased from -US$2.23 to -US$3.82 per share. Revenue forecast of US$94.5m unchanged since last update. Pharmaceuticals industry in the US expected to see average net income growth of 9.5% next year. Consensus price target down from US$11.00 to US$8.00. Share price rose 16% to US$0.56 over the past week.分析記事 • May 19Earnings Release: Here's Why Analysts Cut Their Aytu BioPharma, Inc. (NASDAQ:AYTU) Price Target To US$8.00It's been a pretty great week for Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shareholders, with its shares surging 18% to...Reported Earnings • May 17Third quarter 2022 earnings: EPS and revenues miss analyst expectationsThird quarter 2022 results: US$1.79 loss per share (down from US$1.41 loss in 3Q 2021). Revenue: US$24.2m (up 80% from 3Q 2021). Net loss: US$53.1m (loss widened 109% from 3Q 2021). Revenue missed analyst estimates by 1.2%. Earnings per share (EPS) also missed analyst estimates by 337%. Over the next year, revenue is forecast to grow 12%, compared to a 13% growth forecast for the industry in the US.Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Gary Cantrell was the last director to join the board, commencing their role in 2016. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Major Estimate Revision • Feb 22Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$106.8m to US$94.5m. EPS estimate increased from -US$2.54 to -US$2.36 per share. Pharmaceuticals industry in the US expected to see average net income growth of 16% next year. Consensus price target of US$11.00 unchanged from last update. Share price rose 6.5% to US$1.32 over the past week.Reported Earnings • Feb 15Second quarter 2022 earnings: EPS and revenues miss analyst expectationsSecond quarter 2022 results: US$0.44 loss per share (up from US$0.72 loss in 2Q 2021). Revenue: US$23.1m (up 53% from 2Q 2021). Net loss: US$11.5m (loss widened 21% from 2Q 2021). Revenue missed analyst estimates by 15%. Earnings per share (EPS) also missed analyst estimates by 24%. Over the next year, revenue is forecast to grow 37%, compared to a 17% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has fallen by 50% per year, which means it is significantly lagging earnings.Price Target Changed • Jan 25Price target decreased to US$11.00Down from US$17.40, the current price target is provided by 1 analyst. New target price is 824% above last closing price of US$1.19. Stock is down 86% over the past year. The company is forecast to post a net loss per share of US$2.54 next year compared to a net loss per share of US$3.48 last year.Reported Earnings • Nov 18First quarter 2022 earnings released: US$1.09 loss per share (vs US$0.35 loss in 1Q 2021)The company reported a mediocre first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2022 results: Revenue: US$21.9m (up 62% from 1Q 2021). Net loss: US$27.9m (loss widened US$23.5m from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 102% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.Reported Earnings • Sep 28Full year 2021 earnings released: US$3.48 loss per share (vs US$3.01 loss in FY 2020)The company reported a decent full year result with improved revenues, although losses increased and control over costs was weaker. Full year 2021 results: Revenue: US$65.6m (up 138% from FY 2020). Net loss: US$58.3m (loss widened 328% from FY 2020). Over the last 3 years on average, earnings per share has increased by 113% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings.Board Change • Sep 15Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Gary Cantrell was the last director to join the board, commencing their role in 2016. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.分析記事 • Sep 11Is Aytu Biopharma (NASDAQ:AYTU) Using Debt In A Risky Way?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Board Change • Sep 10Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Gary Cantrell was the last director to join the board, commencing their role in 2016. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Sep 08Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Gary Cantrell was the last director to join the board, commencing their role in 2016. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Sep 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Gary Cantrell was the last director to join the board, commencing their role in 2016. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Executive Departure • Sep 01Independent Director Steven Boyd has left the companyOn the 30th of August, Steven Boyd's tenure as Independent Director ended after 2.5 years in the role. We don't have any record of a personal shareholding under Steven's name. A total of 5 executives have left over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.業績と収益の成長予測NasdaqCM:AYTU - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/20289412N/AN/A16/30/202771-4N/A236/30/202654-19N/A-633/31/202657-34-12N/A12/31/202563-25-4-1N/A9/30/202564-13-4-1N/A6/30/202566-14-5-2N/A3/31/202582-1-6-6N/A12/31/202461-401N/A9/30/202464-4-3-2N/A6/30/202465-13-2-1N/A3/31/202481-1299N/A12/31/202390-1766N/A9/30/202398-2444N/A6/30/202374-8-5-5N/A3/31/2023104-31-22-22N/A12/31/2022106-77-28-28N/A9/30/2022102-82-34-34N/A6/30/202297-109-29-29N/A3/31/202293-112-30-28N/A12/31/202182-84-30-28N/A9/30/202174-82-24-22N/A6/30/202166-58-28-26N/A3/31/202157-42-27-27N/A12/31/202052-22-30-30N/A9/30/202040-13-33-33N/A6/30/202028-14-28-28N/A3/31/202014-25-24-24N/A12/31/20199-24N/A-16N/A9/30/20197-29N/A-14N/A6/30/20197-27N/A-14N/A3/31/20197-12N/A-15N/A12/31/20185-10N/A-16N/A9/30/20184-9N/A-14N/A6/30/20184-10N/A-16N/A3/31/20184-17N/A-15N/A12/31/20174-20N/A-13N/A9/30/20174-21N/A-13N/A6/30/20173-23N/A-14N/A3/31/20173-31N/A-13N/A12/31/20163-33N/A-13N/A9/30/20163-32N/A-14N/A6/30/20163-28N/A-11N/A3/31/20162-15N/A-10N/A12/31/20151-10N/A-9N/A9/30/20151-8N/A-7N/A6/30/20150-8N/A-7N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: AYTUは今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 3.5% ) よりも高い成長率であると考えられます。収益対市場: AYTU今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。高成長収益: AYTU今後 3 年以内に収益を上げることが予想されます。収益対市場: AYTUの収益 ( 23.6% ) US市場 ( 12.9% ) よりも速いペースで成長すると予測されています。高い収益成長: AYTUの収益 ( 23.6% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: AYTUの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/18 13:34終値2026/06/18 00:00収益2026/03/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Aytu BioPharma, Inc. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関Edward WooAscendiant Capital Markets LLCJeffrey CohenLadenburg Thalmann & CompanyThomas FlatenLake Street Capital Markets, LLC2 その他のアナリストを表示
Major Estimate Revision • May 20Consensus EPS estimates upgraded to US$1.40 lossThe consensus outlook for fiscal year 2026 has been updated. 2026 losses forecast to reduce from -US$1.68 to -US$1.40 per share. Revenue forecast steady at US$54.1m. Pharmaceuticals industry in the US expected to see average net income decline 13% next year. Consensus price target of US$9.33 unchanged from last update. Share price fell 4.4% to US$2.15 over the past week.
Major Estimate Revision • Apr 19Consensus EPS estimates upgraded to US$1.68 loss, revenue downgradedThe consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast fell from US$57.1m to US$54.0m. 2026 losses expected to reduce from -US$1.90 to -US$1.68 per share. Pharmaceuticals industry in the US expected to see average net income decline 14% next year. Consensus price target down from US$9.67 to US$9.33. Share price was steady at US$2.60 over the past week.
Major Estimate Revision • Feb 10Consensus EPS estimates fall by 85%, revenue upgradedThe consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast increased from US$55.3m to US$59.1m. Forecast EPS reduced from -US$1.03 to -US$1.90 per share. Pharmaceuticals industry in the US expected to see average net income growth of 1.6% next year. Consensus price target of US$9.33 unchanged from last update. Share price fell 13% to US$2.29 over the past week.
Major Estimate Revision • Jan 22Consensus EPS estimates upgraded to US$1.03 lossThe consensus outlook for fiscal year 2026 has been updated. 2026 losses forecast to reduce from -US$1.14 to -US$1.03 per share. Revenue forecast unchanged from US$55.3m at last update. Pharmaceuticals industry in the US expected to see average net income growth of 1.1% next year. Consensus price target of US$9.33 unchanged from last update. Share price was steady at US$2.71 over the past week.
分析記事 • Nov 17Aytu BioPharma, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This YearAytu BioPharma, Inc. ( NASDAQ:AYTU ) came out with its quarterly results last week, and we wanted to see how the...
Major Estimate Revision • Sep 30Consensus revenue estimates fall by 22%The consensus outlook for revenues in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from US$70.5m to US$55.2m. Forecast losses increased from -US$0.85 to -US$1.55 per share. Pharmaceuticals industry in the US expected to see average net income decline 3.2% next year. Consensus price target down from US$9.67 to US$9.17. Share price fell 25% to US$1.88 over the past week.
Major Estimate Revision • May 20Consensus EPS estimates upgraded to US$1.40 lossThe consensus outlook for fiscal year 2026 has been updated. 2026 losses forecast to reduce from -US$1.68 to -US$1.40 per share. Revenue forecast steady at US$54.1m. Pharmaceuticals industry in the US expected to see average net income decline 13% next year. Consensus price target of US$9.33 unchanged from last update. Share price fell 4.4% to US$2.15 over the past week.
Reported Earnings • May 15Third quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2026 results: US$0.53 loss per share (down from US$0.64 profit in 3Q 2025). Revenue: US$12.4m (down 33% from 3Q 2025). Net loss: US$5.62m (down 243% from profit in 3Q 2025). Revenue exceeded analyst estimates by 3.0%. Earnings per share (EPS) missed analyst estimates by 3.9%. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 8.7% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.
お知らせ • May 07Aytu BioPharma, Inc. to Report Q3, 2026 Results on May 13, 2026Aytu BioPharma, Inc. announced that they will report Q3, 2026 results at 4:00 PM, US Eastern Standard Time on May 13, 2026
Major Estimate Revision • Apr 19Consensus EPS estimates upgraded to US$1.68 loss, revenue downgradedThe consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast fell from US$57.1m to US$54.0m. 2026 losses expected to reduce from -US$1.90 to -US$1.68 per share. Pharmaceuticals industry in the US expected to see average net income decline 14% next year. Consensus price target down from US$9.67 to US$9.33. Share price was steady at US$2.60 over the past week.
Major Estimate Revision • Feb 10Consensus EPS estimates fall by 85%, revenue upgradedThe consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast increased from US$55.3m to US$59.1m. Forecast EPS reduced from -US$1.03 to -US$1.90 per share. Pharmaceuticals industry in the US expected to see average net income growth of 1.6% next year. Consensus price target of US$9.33 unchanged from last update. Share price fell 13% to US$2.29 over the past week.
New Risk • Feb 08New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: US$25m Forecast net loss in 2 years: US$432k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (75% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$432k net loss in 2 years). Market cap is less than US$100m (US$25.7m market cap).
Reported Earnings • Feb 04Second quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behindSecond quarter 2026 results: US$1.06 loss per share (down from US$0.11 profit in 2Q 2025). Revenue: US$15.2m (down 6.5% from 2Q 2025). Net loss: US$10.6m (down US$11.2m from profit in 2Q 2025). Revenue exceeded analyst estimates by 25%. Earnings per share (EPS) missed analyst estimates by 75%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 8.8% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 104% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
お知らせ • Jan 28Aytu BioPharma, Inc. to Report Q2, 2026 Results on Feb 03, 2026Aytu BioPharma, Inc. announced that they will report Q2, 2026 results After-Market on Feb 03, 2026
Major Estimate Revision • Jan 22Consensus EPS estimates upgraded to US$1.03 lossThe consensus outlook for fiscal year 2026 has been updated. 2026 losses forecast to reduce from -US$1.14 to -US$1.03 per share. Revenue forecast unchanged from US$55.3m at last update. Pharmaceuticals industry in the US expected to see average net income growth of 1.1% next year. Consensus price target of US$9.33 unchanged from last update. Share price was steady at US$2.71 over the past week.
分析記事 • Dec 20Aytu BioPharma, Inc. (NASDAQ:AYTU) Stock Catapults 28% Though Its Price And Business Still Lag The IndustryAytu BioPharma, Inc. ( NASDAQ:AYTU ) shares have had a really impressive month, gaining 28% after a shaky period...
分析記事 • Nov 17Aytu BioPharma, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This YearAytu BioPharma, Inc. ( NASDAQ:AYTU ) came out with its quarterly results last week, and we wanted to see how the...
New Risk • Nov 16New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: US$13m Forecast net loss in 2 years: US$1.6m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (66% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$1.6m net loss in 2 years). Market cap is less than US$100m (US$21.3m market cap).
お知らせ • Nov 06Aytu BioPharma, Inc. to Report Q1, 2026 Results on Nov 13, 2025Aytu BioPharma, Inc. announced that they will report Q1, 2026 results After-Market on Nov 13, 2025
分析記事 • Oct 30There's No Escaping Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Muted Revenues Despite A 27% Share Price RiseThose holding Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shares would be relieved that the share price has rebounded 27% in...
お知らせ • Oct 27Aytu BioPharma, Inc., Annual General Meeting, Dec 10, 2025Aytu BioPharma, Inc., Annual General Meeting, Dec 10, 2025. Location: 7900 east union avenue, suite 920, colorado 80237, denver United States
Major Estimate Revision • Sep 30Consensus revenue estimates fall by 22%The consensus outlook for revenues in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from US$70.5m to US$55.2m. Forecast losses increased from -US$0.85 to -US$1.55 per share. Pharmaceuticals industry in the US expected to see average net income decline 3.2% next year. Consensus price target down from US$9.67 to US$9.17. Share price fell 25% to US$1.88 over the past week.
Reported Earnings • Sep 24Full year 2025 earnings: EPS and revenues miss analyst expectationsFull year 2025 results: US$2.26 loss per share (improved from US$2.86 loss in FY 2024). Revenue: US$66.4m (down 18% from FY 2024). Net loss: US$14.2m (loss narrowed 11% from FY 2024). Revenue missed analyst estimates by 4.0%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 8.6% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 125% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.
お知らせ • Sep 17Aytu BioPharma, Inc. to Report Q4, 2025 Results on Sep 23, 2025Aytu BioPharma, Inc. announced that they will report Q4, 2025 results After-Market on Sep 23, 2025
分析記事 • Jul 29Improved Revenues Required Before Aytu BioPharma, Inc. (NASDAQ:AYTU) Stock's 25% Jump Looks JustifiedAytu BioPharma, Inc. ( NASDAQ:AYTU ) shares have continued their recent momentum with a 25% gain in the last month...
Breakeven Date Change • Jun 30Forecast breakeven date pushed back to 2026The analyst covering Aytu BioPharma previously expected the company to break even in 2025. New forecast suggests the company will make a profit of US$1.66m in 2026. Average annual earnings growth of 77% is required to achieve expected profit on schedule.
New Risk • Jun 13New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 61% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (30% average weekly change). Shareholders have been substantially diluted in the past year (61% increase in shares outstanding). Minor Risk Market cap is less than US$100m (US$17.5m market cap).
お知らせ • Jun 03Aytu BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $12 million.Aytu BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $12 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 6,741,573 Price\Range: $1.78 Discount Per Security: $0.1246 Security Name: Prefunded Warrants Security Type: Equity Warrant Securities Offered: 6,741,573
Reported Earnings • May 15Third quarter 2025 earnings: EPS and revenues exceed analyst expectationsThird quarter 2025 results: EPS: US$0.64 (up from US$0.52 loss in 3Q 2024). Revenue: US$18.5m (up 2.6% from 3Q 2024). Net income: US$3.94m (up US$6.83m from 3Q 2024). Profit margin: 21% (up from net loss in 3Q 2024). Revenue exceeded analyst estimates by 34%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to stay flat during the next 3 years compared to a 8.3% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 122% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.
分析記事 • May 14We Think Some Shareholders May Hesitate To Increase Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO CompensationKey Insights Aytu BioPharma will host its Annual General Meeting on 21st of May Total pay for CEO Josh Disbrow includes...
お知らせ • May 08Aytu BioPharma, Inc. to Report Q3, 2025 Results on May 14, 2025Aytu BioPharma, Inc. announced that they will report Q3, 2025 results After-Market on May 14, 2025
分析記事 • May 04Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Price Is Right But Growth Is Lacking After Shares Rocket 27%Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shareholders are no doubt pleased to see that the share price has bounced 27% in...
お知らせ • Mar 31Aytu BioPharma, Inc., Annual General Meeting, May 21, 2025Aytu BioPharma, Inc., Annual General Meeting, May 21, 2025. Location: at the office of aytu biopharma, inc., 7900 east union avenue, suite 920, colorado 80237, denver United States
Reported Earnings • Feb 13Second quarter 2025 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2025 results: EPS: US$0.11. Revenue: US$16.2m (down 14% from 2Q 2024). Net income: US$665.0k (up 7.4% from 2Q 2024). Profit margin: 4.1% (up from 3.3% in 2Q 2024). Revenue exceeded analyst estimates by 4.3%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to stay flat during the next 3 years compared to a 8.6% growth forecast for the Pharmaceuticals industry in the US.
分析記事 • Jan 18Aytu BioPharma, Inc. (NASDAQ:AYTU) Shares Fly 28% But Investors Aren't Buying For GrowthAytu BioPharma, Inc. ( NASDAQ:AYTU ) shareholders are no doubt pleased to see that the share price has bounced 28% in...
Reported Earnings • Nov 15First quarter 2025 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2025 results: EPS: US$0.18 (up from US$1.48 loss in 1Q 2024). Revenue: US$16.6m (down 25% from 1Q 2024). Net income: US$1.09m (up US$9.21m from 1Q 2024). Profit margin: 6.6% (up from net loss in 1Q 2024). Revenue exceeded analyst estimates by 20%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is expected to decline by 7.4% p.a. on average during the next 2 years, while revenues in the Pharmaceuticals industry in the US are expected to grow by 10%.
分析記事 • Nov 15Investors Don't See Light At End Of Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Tunnel And Push Stock Down 32%To the annoyance of some shareholders, Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shares are down a considerable 32% in the...
お知らせ • Nov 14Aytu Biopharma, Inc. Announces Chief Financial Officer ChangesAytu BioPharma, Inc. announced the promotion of Ryan Selhorn, current Executive Vice President of Finance and Business Optimization, to the role of Chief Financial Officer, replacing Mark Oki, who will depart the company. Prior to Ryan's appointment as Chief Financial Officer, he served as Aytu's Executive Vice President, Finance and Business Optimization since November 2022. Prior to this, Ryan was Aytu's Senior Vice President, Finance and Operations, Consumer Healthcare Division from February 2022 to November 2022 and as Vice President, Finance, Consumer Healthcare Division from February 2020 to February 2022. Ryan served as Vice President and Chief Financial Officer from April 2018 at Innovus Pharmaceuticals, Inc. until Aytu's acquisition of Innovus in February 2020. From August 2013 to April 2018, Ryan served as Chief Financial Officer and Chief Accounting Officer of Signature Analytics, where he also served as Chief Financial Officer of Medicinova, Inc. Ryan worked at Grant Thornton LLP, from October 2003 to July 2013, most recently in the role of Senior Manager, Transaction Advisory Services. Ryan received his B.S./B.A., Accounting and Finance from Georgetown University and is a Certified Public Accountant (inactive).
お知らせ • Nov 07Aytu BioPharma, Inc. to Report Q1, 2025 Results on Nov 13, 2024Aytu BioPharma, Inc. announced that they will report Q1, 2025 results After-Market on Nov 13, 2024
分析記事 • Nov 01Is Aytu BioPharma (NASDAQ:AYTU) Using Debt Sensibly?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Reported Earnings • Sep 27Full year 2024 earnings: EPS misses analyst expectationsFull year 2024 results: US$2.86 loss per share (improved from US$5.11 loss in FY 2023). Revenue: US$81.0m (down 25% from FY 2023). Net loss: US$15.8m (loss narrowed 7.1% from FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 15%. Revenue is expected to decline by 8.2% p.a. on average during the next 2 years, while revenues in the Pharmaceuticals industry in the US are expected to grow by 10%.
お知らせ • Sep 20Aytu BioPharma, Inc. to Report Q4, 2024 Results on Sep 26, 2024Aytu BioPharma, Inc. announced that they will report Q4, 2024 results After-Market on Sep 26, 2024
お知らせ • Aug 07An unknown buyer acquired Innovus Pharmaceuticals, Inc. from Aytu BioPharma, Inc. (NasdaqCM:AYTU).An unknown buyer acquired Innovus Pharmaceuticals, Inc. from Aytu BioPharma, Inc. (NasdaqCM:AYTU) on August 6, 2024. Aytu to receive revenue-based royalty payments on future sales of former Consumer Health business products. An unknown buyer completed the acquisition of Innovus Pharmaceuticals, Inc. from Aytu BioPharma, Inc. (NasdaqCM:AYTU) on August 6, 2024.
New Risk • Jun 23New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 8.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (8.1% increase in shares outstanding). Market cap is less than US$100m (US$17.4m market cap).
分析記事 • Jun 20It's Probably Less Likely That Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Will See A Huge Pay Rise This YearKey Insights Aytu BioPharma will host its Annual General Meeting on 26th of June Salary of US$590.0k is part of CEO...
分析記事 • Jun 14Here's Why Aytu BioPharma (NASDAQ:AYTU) Has A Meaningful Debt BurdenSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Major Estimate Revision • May 22Consensus EPS estimates fall by 12%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from US$83.6m to US$81.3m. Losses expected to increase from US$2.23 per share to US$2.49. Pharmaceuticals industry in the US expected to see average net income growth of 3.3% next year. Consensus price target of US$8.00 unchanged from last update. Share price rose 2.3% to US$3.13 over the past week.
Reported Earnings • May 17Third quarter 2024 earnings: EPS and revenues exceed analyst expectationsThird quarter 2024 results: US$0.52 loss per share (improved from US$1.93 loss in 3Q 2023). Revenue: US$18.0m (down 21% from 3Q 2023). Net loss: US$2.89m (loss narrowed 60% from 3Q 2023). Revenue exceeded analyst estimates by 3.7%. Earnings per share (EPS) also surpassed analyst estimates by 19%. Revenue is expected to decline by 9.9% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in the US are expected to grow by 9.4%.
お知らせ • May 14Aytu BioPharma, Inc., Annual General Meeting, Jun 26, 2024Aytu BioPharma, Inc., Annual General Meeting, Jun 26, 2024. Location: dorsey & whitney llp, 1400 wewatta street, suite 400, colorado 80202, , denver United States
お知らせ • May 10Aytu BioPharma, Inc. to Report Q3, 2024 Results on May 15, 2024Aytu BioPharma, Inc. announced that they will report Q3, 2024 results After-Market on May 15, 2024
分析記事 • Feb 17US$8.00 - That's What Analysts Think Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Worth After These ResultsAytu BioPharma, Inc. ( NASDAQ:AYTU ) just released its latest quarterly results and things are looking bullish. Results...
分析記事 • Feb 16Aytu BioPharma, Inc. (NASDAQ:AYTU) Surges 25% Yet Its Low P/S Is No Reason For ExcitementDespite an already strong run, Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shares have been powering on, with a gain of 25% in...
Reported Earnings • Feb 16Second quarter 2024 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2024 results: US$0.04 loss per share (improved from US$2.15 loss in 2Q 2023). Revenue: US$22.9m (down 13% from 2Q 2023). Net loss: US$220.0k (loss narrowed 97% from 2Q 2023). Revenue exceeded analyst estimates by 5.5%. Earnings per share (EPS) also surpassed analyst estimates by 84%. Revenue is expected to decline by 12% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in the US are expected to grow by 9.0%.
お知らせ • Feb 08Aytu BioPharma, Inc. to Report Q2, 2024 Results on Feb 14, 2024Aytu BioPharma, Inc. announced that they will report Q2, 2024 results After-Market on Feb 14, 2024
分析記事 • Jan 23Does Aytu BioPharma (NASDAQ:AYTU) Have A Healthy Balance Sheet?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Price Target Changed • Dec 29Price target decreased by 95% to US$5.00Down from US$110, the current price target is provided by 1 analyst. New target price is 67% above last closing price of US$2.99. Stock is down 19% over the past year. The company is forecast to post a net loss per share of US$2.17 next year compared to a net loss per share of US$5.11 last year.
お知らせ • Nov 08Aytu BioPharma, Inc. to Report Q1, 2024 Results on Nov 14, 2023Aytu BioPharma, Inc. announced that they will report Q1, 2024 results After-Market on Nov 14, 2023
お知らせ • Oct 27Aytu BioPharma, Inc. Announces Approval of the Cotempla XR-ODT Manufacturing Site Transfer Prior Approval SupplementAytu BioPharma, Inc. announced receipt of U.S. Food & Drug Administration (FDA) approval of the Cotempla XR-ODT® ("Cotempla") Prior Approval Supplement (PAS). This approval enables the transfer of manufacturing of Cotempla to the Company's third-party manufacturer and follows a similar achievement for Adzenys XR- ODT® ("Adzenys") which received PAS approval in April 2023. Aytu is committed to a consistent and orderly transition of production to the new manufacturing facility in the coming months to ensure adequate inventory is available to meet the recent surge in prescription growth experienced for both Adzenys and Cotempla.
お知らせ • Oct 01Aytu BioPharma, Inc. announced delayed annual 10-K filingOn 09/29/2023, Aytu BioPharma, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
分析記事 • Sep 29Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Share Price Boosted 59% But Its Business Prospects Need A Lift TooAytu BioPharma, Inc. ( NASDAQ:AYTU ) shareholders have had their patience rewarded with a 59% share price jump in the...
Reported Earnings • Sep 28Full year 2023 earnings: EPS and revenues exceed analyst expectationsFull year 2023 results: US$5.11 loss per share (improved from US$74.95 loss in FY 2022). Revenue: US$107.4m (up 11% from FY 2022). Net loss: US$17.1m (loss narrowed 85% from FY 2022). Revenue exceeded analyst estimates by 2.9%. Earnings per share (EPS) also surpassed analyst estimates by 17%. Revenue is expected to decline by 6.1% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in the US are expected to grow by 7.3%.
お知らせ • Sep 22Aytu BioPharma, Inc. to Report Q4, 2023 Results on Sep 27, 2023Aytu BioPharma, Inc. announced that they will report Q4, 2023 results After-Market on Sep 27, 2023
お知らせ • Jul 11Aytu BioPharma, Inc. Announces Submission of Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval SupplementAytu BioPharma, Inc. submitted the Cotempla XR-ODT®? ("Cotempla") Prior Approval Supplement (PAS) to the U.S. Food & Drug Administration (FDA). If approved, the PAS would enable Aytu to transfer the production of Cotempla to the Company's third-party manufacturer. The Company expects a six-month review of the PAS submission, which would enable FDA approval by late calendar 2023 or early calendar 2024. The Company previously announced the FDA approval of the Adzenys XR-ODT (Adzenys) site transfer PAS and has begun shifting Adzenys production to the Company's contract manufacturer.
お知らせ • Jun 14Aytu BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $3.999955 million.Aytu BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $3.999955 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,743,695 Price\Range: $1.84 Discount Per Security: $0.1288 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 430,217 Price\Range: $1.8399 Discount Per Security: $0.1288
お知らせ • Jun 10+ 1 more updateAytu BioPharma, Inc. Appoints Abhinav "Abi" Jain as Board of DirectorsAytu BioPharma, Inc. announced the appointment of Abhinav "Abi" Jain of Nantahala Capital Management, LLC as the Company's Board of Directors as Board of Directors. Abi Jain is an Analyst at Nantahala, focused on investments in various sectors, including specialty and generic pharmaceuticals. Prior to joining Nantahala in 2019, Mr. Jain was an Associate at Angelo, Gordon &Co., an alternative asset manager based in New York from 2015-2017. At Angelo, Gordon &Co., Mr. Jain focused on private equity and structured credit investments. He graduated from Massachusetts Institute of Technology in 2012 with an S.B. in Chemical-Biological Engineering and from The Wharton School of the University of Pennsylvania in 2019 with an M.B.A. with honors in Finance and Entrepreneurial Management.
Breakeven Date Change • Jun 10Forecast to breakeven in 2025The 2 analysts covering Aytu BioPharma expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 68% per year to 2024. The company is expected to make a profit of US$8.20m in 2025. Average annual earnings growth of 66% is required to achieve expected profit on schedule.
Major Estimate Revision • May 18Consensus EPS estimates fall by 31%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from US$108.1m to US$102.8m. Losses expected to increase from US$4.78 per share to US$6.24. Pharmaceuticals industry in the US expected to see average net income decline 7.8% next year. Consensus price target of US$70.00 unchanged from last update. Share price fell 14% to US$1.81 over the past week.
Breakeven Date Change • May 15Forecast to breakeven in 2024The 2 analysts covering Aytu BioPharma expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 88% to 2023. The company is expected to make a profit of US$900.0k in 2024. Average annual earnings growth of 149% is required to achieve expected profit on schedule.
お知らせ • Feb 16Aytu BioPharma, Inc. announced delayed 10-Q filingOn 02/15/2023, Aytu BioPharma, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jan 26Aytu Biopharma Regains Nasdaq Minimum Bid Price ComplianceAytu BioPharma, Inc. (the Company or "Aytu") announced that it received a written notification from the Listing Qualifications Department of The Nasdaq Stock Market, LLC ("Nasdaq") notifying the Company that it has regained compliance with the Nasdaq's minimum bid price requirement. On January 23, 2023, Nasdaq confirmed in that for the ten consecutive business days, from January 6, 2023 to January 20, 2023, the closing bid price of the Company's common stock has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2), and the matter is closed.
お知らせ • Jan 11Aytu Biopharma, Inc. Continues Availability of Adzenys XR-ODT(R) as the Only FDA-Approved Orally Disintegrating Tablet (ODT) Medication That Is Bioequivalent to Adderall XR(R) for Adhd PatientsAytu RxConnect Providing Access Relief to Patients Amid Ongoing Generic Adderall® Supply Disruption. Millions of ADHD patients in the United States rely on FDA approved treatments to control their ADHD symptoms and many of them are currently struggling to fill their prescription due to a prolonged supply disruption for generic Adderall XR (mixed salts of a single-entity amphetamine product) extended-release capsules, CII. Many of these patients may not be aware that there's an FDA-approved, bioequivalent treatment option which is widely available. As the only FDA-approved Orally Disintegrating Tablet bioequivalent to Adderall XR, Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets, CII is bridging the access gap resulting from the current supply disruption, as well as the shortage of Adderall IR. Aytu BioPharma, Inc. Adzenys XR-ODT is available as a potential treatment option to Adderall XR in six equivalent strengths. As healthcare insurance resets in January, many ADHD patients with high deductibles may face another challenge in accessing their medication. However, patients facing insurance challenges can gain access to Adzenys XR-ODT via Aytu's proprietary RxConnect program and the company's network of more than 1,000 retail pharmacies. The program is designed specifically to help patients navigate complex treatment journeys. It enables affordable, predictable patient access to Aytu Rx products and reduces out-of-pocket costs by 50 percent. In most cases, commercially insured patients will pay no more than $35 for their monthly prescription of Adzenys XR-ODT.
Major Estimate Revision • Nov 21Consensus forecasts updatedThe consensus outlook for 2023 has been updated. 2023 losses forecast to reduce from -US$0.49 to -US$0.22 per share. Revenue forecast steady at US$109.0m. Pharmaceuticals industry in the US expected to see average net income growth of 4.5% next year. Consensus price target of US$5.50 unchanged from last update. Share price rose 11% to US$0.23 over the past week.
Breakeven Date Change • Nov 16Forecast to breakeven in 2025The analyst covering Aytu BioPharma expects the company to break even for the first time. New forecast suggests losses will reduce by 74% per year to 2024. The company is expected to make a profit of US$2.80m in 2025. Average annual earnings growth of 76% is required to achieve expected profit on schedule.
Reported Earnings • Nov 16First quarter 2023 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2023 results: US$0.057 loss per share (improved from US$1.09 loss in 1Q 2022). Revenue: US$27.7m (up 26% from 1Q 2022). Net loss: US$2.88m (loss narrowed 90% from 1Q 2022). Revenue exceeded analyst estimates by 14%. Earnings per share (EPS) also surpassed analyst estimates by 67%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Pharmaceuticals industry in the US.
Seeking Alpha • Oct 13Aytu stock falls amid suspending clinical programs to save costsAytu BioPharma (NASDAQ:AYTU) stock dipped ~5% on Oct. 13 after the company said it was indefinitely suspending certain clinical development programs, thus expecting to save over $20M. The suspension includes AR101/enzastaurin for treat Vascular Ehlers-Danlos Syndrome (VEDS), Healight, and NT0502. Aytu is expecting to generate positive quarterly adjusted EBITDA in H1 calendar year 2023. "This strategic realignment enables us to dedicate our resources to growing our prescription and consumer health segments. Coupled with the suspension of clinical development activities and continued execution against our previously planned $15 million cost cutting program, this shift enables the Company to achieve near-term positive Adjusted EBITDA," said Aytu CEO Josh Disbrow in an Oct. 13 press release. The company expects to provide a detailed financial outlook of its strategy at its quarterly investors call scheduled for mid-November.
Major Estimate Revision • Oct 04Consensus estimates of losses per share improve by 28%The consensus outlook for earnings per share (EPS) in 2023 has improved. 2023 revenue forecast increased from US$107.1m to US$110.1m. EPS estimate increased from -US$0.68 per share to -US$0.49 per share. Pharmaceuticals industry in the US expected to see average net income decline 2.3% next year. Consensus price target of US$5.50 unchanged from last update. Share price rose 2.6% to US$0.19 over the past week.
Reported Earnings • Sep 28Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2022 results: US$3.75 loss per share (further deteriorated from US$3.48 loss in FY 2021). Revenue: US$96.7m (up 47% from FY 2021). Net loss: US$110.2m (loss widened 89% from FY 2021). Revenue exceeded analyst estimates by 2.1%. Earnings per share (EPS) missed analyst estimates by 4.9%. Revenue is forecast to grow 8.7% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Pharmaceuticals industry in the US.
Seeking Alpha • Sep 27Aytu BioScience GAAP EPS of -$0.49 misses by $0.12, revenue of $27.45M beats by $1.95MAytu BioScience press release (NASDAQ:AYTU): FQ4 GAAP EPS of -$0.49 misses by $0.12. Revenue of $27.45M (+16.9% Y/Y) beats by $1.95M. Cash and cash equivalents at the end of the fiscal year ended June 30, 2022 were $19.4 million. Subsequent to the end of the year, the Company raised $10.0 million in gross proceeds in a registered public offering. Prescription segment Adjusted EBITDA was a positive $1.1 million, while Consumer Health was $(2.1) million resulting in a combined Adjusted EBITDA of $(1.0) million for the Company's commercial business. This compares to Adjusted EBITDA of $(5.5) million for the Prescription segment and $(2.7) million for the Consumer Health segment in Q4 2021, resulting in a combined Adjusted EBITDA of $(8.2) million for the Company's commercial business. Shares +5.26%.
Seeking Alpha • Sep 14Aytu Biopharma adds fourth patent license for AR101 to treat rare genetic disorderAytu BioPharma (NASDAQ:AYTU) announced on Wednesday the addition of a fourth patent for AR101/Enzastaurin to treat Vascular Ehlers-Danlos Syndrome, rare genetic disorder treatment. The patent has an expiry date of September 2041. The company expects to advance the PREVEnt Trial in VEDS for AR101 and dose the first patient by early 2023. "Adding this fourth patent to the portfolio deepens and broadens the intellectual property surrounding AR101/Enzastaurin for the treatment of inherited vascular disorders, including VEDS, for which we are advancing AR101 as an initial indication," the company said. Vascular Ehlers-Danlos syndrome (vEDS) is the most severe type of a hereditary disorder of the connective tissue. (AYTU) had risen 3.3% before the bell.
Seeking Alpha • Aug 16Aytu gets US patent for AR101/Enzastaurin for circulatory system disordersAytu BioPharma (NASDAQ:AYTU) said the U.S. Patent and Trademark Office issued a patent, a first for AR101/Enzastaurin. The U.S. patent No. 11,273,148 titled 'Targeted Epigenetic Therapy for Inherited Aortic Aneurism Condition,' covers methods for the targeted epigenetic therapy of inherited aortic aneurysm and other diseases with altered regulation of TGFβ genes, including Ehlers-Danlos Syndrome, the company said in an Aug. 16 press release. Aytu added that it was the first issued patent supporting the portfolio and expires in August of 2038, if not extended. "This issued patent underpins the broad potential clinical application across numerous inherited vascular disorders, including vascular Ehlers-Danlos Syndrome ("VEDS"), for which we are advancing AR101 as an initial indication. We expect to progress the PREVEnt Trial in VEDS for AR101 and dose the first patient by early 2023," said Aytu CEO Josh Disbrow. AYTU +0.59% to $0.29 premarket Aug. 16
Seeking Alpha • Aug 09Aytu BioPharma plunges on pricing $10M stock and warrants offeringAytu BioPharma (NASDAQ:AYTU) priced its underwritten public offering of 21.5M shares to certain investors, pre-funded warrants to purchase 1.75M shares and accompanying warrants to purchase 23.2M shares,. The combined public offering price for each share of common stock and accompanying common warrant is $0.43 and combined offering price for each pre-funded warrant and accompanying common warrant is $0.429. Gross proceeds are expected to be ~$10M. Offer is expected to close on Aug.11. Net proceeds to be used for advancing the development of its pipeline assets, including for advancing the PREVEnt Trial evaluating AR101 for the treatment of vascular Ehlers-Danlos Syndrome, for growth of the company's commercial business, and for working capital and general corporate purposes.
Major Estimate Revision • May 23Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 expected loss increased from -US$2.23 to -US$3.82 per share. Revenue forecast of US$94.5m unchanged since last update. Pharmaceuticals industry in the US expected to see average net income growth of 9.5% next year. Consensus price target down from US$11.00 to US$8.00. Share price rose 16% to US$0.56 over the past week.
分析記事 • May 19Earnings Release: Here's Why Analysts Cut Their Aytu BioPharma, Inc. (NASDAQ:AYTU) Price Target To US$8.00It's been a pretty great week for Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shareholders, with its shares surging 18% to...
Reported Earnings • May 17Third quarter 2022 earnings: EPS and revenues miss analyst expectationsThird quarter 2022 results: US$1.79 loss per share (down from US$1.41 loss in 3Q 2021). Revenue: US$24.2m (up 80% from 3Q 2021). Net loss: US$53.1m (loss widened 109% from 3Q 2021). Revenue missed analyst estimates by 1.2%. Earnings per share (EPS) also missed analyst estimates by 337%. Over the next year, revenue is forecast to grow 12%, compared to a 13% growth forecast for the industry in the US.
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Gary Cantrell was the last director to join the board, commencing their role in 2016. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Major Estimate Revision • Feb 22Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$106.8m to US$94.5m. EPS estimate increased from -US$2.54 to -US$2.36 per share. Pharmaceuticals industry in the US expected to see average net income growth of 16% next year. Consensus price target of US$11.00 unchanged from last update. Share price rose 6.5% to US$1.32 over the past week.
Reported Earnings • Feb 15Second quarter 2022 earnings: EPS and revenues miss analyst expectationsSecond quarter 2022 results: US$0.44 loss per share (up from US$0.72 loss in 2Q 2021). Revenue: US$23.1m (up 53% from 2Q 2021). Net loss: US$11.5m (loss widened 21% from 2Q 2021). Revenue missed analyst estimates by 15%. Earnings per share (EPS) also missed analyst estimates by 24%. Over the next year, revenue is forecast to grow 37%, compared to a 17% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has fallen by 50% per year, which means it is significantly lagging earnings.
Price Target Changed • Jan 25Price target decreased to US$11.00Down from US$17.40, the current price target is provided by 1 analyst. New target price is 824% above last closing price of US$1.19. Stock is down 86% over the past year. The company is forecast to post a net loss per share of US$2.54 next year compared to a net loss per share of US$3.48 last year.
Reported Earnings • Nov 18First quarter 2022 earnings released: US$1.09 loss per share (vs US$0.35 loss in 1Q 2021)The company reported a mediocre first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2022 results: Revenue: US$21.9m (up 62% from 1Q 2021). Net loss: US$27.9m (loss widened US$23.5m from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 102% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.
Reported Earnings • Sep 28Full year 2021 earnings released: US$3.48 loss per share (vs US$3.01 loss in FY 2020)The company reported a decent full year result with improved revenues, although losses increased and control over costs was weaker. Full year 2021 results: Revenue: US$65.6m (up 138% from FY 2020). Net loss: US$58.3m (loss widened 328% from FY 2020). Over the last 3 years on average, earnings per share has increased by 113% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings.
Board Change • Sep 15Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Gary Cantrell was the last director to join the board, commencing their role in 2016. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
分析記事 • Sep 11Is Aytu Biopharma (NASDAQ:AYTU) Using Debt In A Risky Way?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Board Change • Sep 10Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Gary Cantrell was the last director to join the board, commencing their role in 2016. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Sep 08Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Gary Cantrell was the last director to join the board, commencing their role in 2016. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Sep 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Gary Cantrell was the last director to join the board, commencing their role in 2016. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Executive Departure • Sep 01Independent Director Steven Boyd has left the companyOn the 30th of August, Steven Boyd's tenure as Independent Director ended after 2.5 years in the role. We don't have any record of a personal shareholding under Steven's name. A total of 5 executives have left over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.